Univariate analysis for specific hazard of relapse
| . | All patients . | t(8;21) . | inv(16)/t(16;16) . | |||
|---|---|---|---|---|---|---|
| . | SHR . | 95% CI . | SHR . | 95% CI . | SHR . | 95% CI . |
| CBF subset | 1.10 | 0.65-1.86 | ||||
| Treatment arm | 0.97 | 0.58-1.64 | 0.82 | 0.38-1.77 | 1.13 | 0.56-2.28 |
| Age* | 1.00 | 0.98-1.02 | 0.99 | 0.96-1.02 | 1.00 | 0.97-1.04 |
| Gender | 1.44 | 0.85-2.43 | 1.15 | 0.53-2.49 | 1.74 | 0.85-3.60 |
| Log(WBC)* | 2.26 | 1.29-3.95 | 3.43 | 1.27-9.26 | 1.86 | 0.96-3.62 |
| BM blasts %* | 1.01 | 0.99-1.02 | 1.01 | 0.99-1.03 | 1.005 | 0.98-1.025 |
| Diagnosis fusion transcript ratio* | 1.00 | 0.99-1.002 | 1.00 | 0.99-1.002 | 1.00 | 0.99-1.004 |
| Additional cytogenetic abnormalities | ||||||
| Loss of Y | 1.02 | 0.45-2.31 | 1.02 | 0.45-2.31 | NA | NA |
| Trisomy 8 | 0.50 | 0.15-1.63 | NA | NA | 0.36 | 0.08-1.49 |
| Trisomy 22 | 0.82 | 0.31-2.15 | NA | NA | 0.82 | 0.31-2.15 |
| del(9q) | 1.49 | 0.56-3.95 | 1.15 | 0.39-3.33 | NA | NA |
| del(7q)/-7 | 1.09 | 0.34-3.51 | 0.87 | 0.12-6.47 | 1.26 | 0.30-5.29 |
| Gene mutations | ||||||
| KIT exon 8 | 1.89 | 0.88-4.09 | 1.90 | 0.53-6.82 | 1.89 | 0.72-4.97 |
| KIT exon 17 | 1.73 | 0.81-3.72 | 2.04 | 0.81-5.14 | 1.24 | 0.30-5.24 |
| KIT, all | 1.78 | 0.98-3.24 | 1.84 | 0.80-4.27 | 1.72 | 0.74-4.02 |
| FLT3-TKD | 1.81 | 0.86-3.80 | 2.32 | 0.55-9.90 | 1.67 | 0.71-3.93 |
| FLT3-ITD | 1.13 | 0.35-3.71 | 1.44 | 0.32-6.43 | 0.81 | 0.11-6.00 |
| FLT3, all | 1.70 | 0.88-3.27 | 1.88 | 0.63-5.67 | 1.60 | 0.71-3.63 |
| RTK, all | 1.89 | 1.11-3.22 | 1.90 | 0.87-4.15 | 1.88 | 0.91-3.89 |
| N-RAS | 1.30 | 0.70-2.41 | 1.15 | 0.40-3.35 | 1.39 | 0.65-2.97 |
| K-RAS | 0.51 | 0.12-2.10 | 1.70 | 0.23-12.64 | 0.29 | 0.04-2.15 |
| RAS, all | 1.07 | 0.59-1.95 | 1.26 | 0.47-3.34 | 0.98 | 0.47-2.07 |
| . | All patients . | t(8;21) . | inv(16)/t(16;16) . | |||
|---|---|---|---|---|---|---|
| . | SHR . | 95% CI . | SHR . | 95% CI . | SHR . | 95% CI . |
| CBF subset | 1.10 | 0.65-1.86 | ||||
| Treatment arm | 0.97 | 0.58-1.64 | 0.82 | 0.38-1.77 | 1.13 | 0.56-2.28 |
| Age* | 1.00 | 0.98-1.02 | 0.99 | 0.96-1.02 | 1.00 | 0.97-1.04 |
| Gender | 1.44 | 0.85-2.43 | 1.15 | 0.53-2.49 | 1.74 | 0.85-3.60 |
| Log(WBC)* | 2.26 | 1.29-3.95 | 3.43 | 1.27-9.26 | 1.86 | 0.96-3.62 |
| BM blasts %* | 1.01 | 0.99-1.02 | 1.01 | 0.99-1.03 | 1.005 | 0.98-1.025 |
| Diagnosis fusion transcript ratio* | 1.00 | 0.99-1.002 | 1.00 | 0.99-1.002 | 1.00 | 0.99-1.004 |
| Additional cytogenetic abnormalities | ||||||
| Loss of Y | 1.02 | 0.45-2.31 | 1.02 | 0.45-2.31 | NA | NA |
| Trisomy 8 | 0.50 | 0.15-1.63 | NA | NA | 0.36 | 0.08-1.49 |
| Trisomy 22 | 0.82 | 0.31-2.15 | NA | NA | 0.82 | 0.31-2.15 |
| del(9q) | 1.49 | 0.56-3.95 | 1.15 | 0.39-3.33 | NA | NA |
| del(7q)/-7 | 1.09 | 0.34-3.51 | 0.87 | 0.12-6.47 | 1.26 | 0.30-5.29 |
| Gene mutations | ||||||
| KIT exon 8 | 1.89 | 0.88-4.09 | 1.90 | 0.53-6.82 | 1.89 | 0.72-4.97 |
| KIT exon 17 | 1.73 | 0.81-3.72 | 2.04 | 0.81-5.14 | 1.24 | 0.30-5.24 |
| KIT, all | 1.78 | 0.98-3.24 | 1.84 | 0.80-4.27 | 1.72 | 0.74-4.02 |
| FLT3-TKD | 1.81 | 0.86-3.80 | 2.32 | 0.55-9.90 | 1.67 | 0.71-3.93 |
| FLT3-ITD | 1.13 | 0.35-3.71 | 1.44 | 0.32-6.43 | 0.81 | 0.11-6.00 |
| FLT3, all | 1.70 | 0.88-3.27 | 1.88 | 0.63-5.67 | 1.60 | 0.71-3.63 |
| RTK, all | 1.89 | 1.11-3.22 | 1.90 | 0.87-4.15 | 1.88 | 0.91-3.89 |
| N-RAS | 1.30 | 0.70-2.41 | 1.15 | 0.40-3.35 | 1.39 | 0.65-2.97 |
| K-RAS | 0.51 | 0.12-2.10 | 1.70 | 0.23-12.64 | 0.29 | 0.04-2.15 |
| RAS, all | 1.07 | 0.59-1.95 | 1.26 | 0.47-3.34 | 0.98 | 0.47-2.07 |
Comparisons were based on cause-specific hazard Cox models, stratified on treatment arm and CBF subset when applicable, and the 12 patients who received allogeneic SCT in first hematologic CR were censored at SCT time.
NA, not applicable; RTK: receptor tyrosine kinase (KIT and/or FLT3).
Tested as continuous variable.